+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

P53 expression in dedifferentiated chondrosarcoma

P53 expression in dedifferentiated chondrosarcoma

Cancer (philadelphia). 76(2): 223-227

Background: p53 acts as a tumor suppressor gene because of to its negative control of the cell cycle and its central role in programmed cell death. It frequently is mutated, as observed in a variety of human neoplasms. The mutations inhibit tumor-suppressor activities of p53, which may gain a new function of tumor promotion. In this study, p53 was investigated in various components of dedifferentiated chondrosarcoma and correlated with their proliferative activities. Methods: Immunohistochemical assays for p53, Ki-67, and proliferating cell nuclear antigen (PCNA) were used in a series of eight dedifferentiated chondrosarcomas of bone. The cartilaginous component was low grade (Grade I-II) in five cases. It was predominantly low grade with foci of a high grade (Grade III) chondrosarcoma in the remaining three cases. The noncartilaginous (dedifferentiated) high grade component consisted of malignant fibrous histiocytoma in five cases and osteosarcoma in three. Results: Regardless of the histological type, diffuse strong nuclear staining for p53 occurred in the high grade noncartilaginous component of all eight of the tumors. The low grade cartilaginous component of six cases was negative for p53, with focal weak staining in the two remaining cases. The high grade cartilaginous component showed strong positive staining for this protein in all three cases. Ki-67 and PCNA expression were similar to that of p53. Conclusions: The percentage of p53 positive staining roughly was parallel to the proliferating fraction of cells in various components of dedifferentiated chondrosarcoma. Moreover, p53 overexpression was consistently present in the high grade noncartilaginous (dedifferentiated) component of the tumor and was accompanied by increased proliferative activity.

(PDF emailed within 0-6 h: $19.90)

Accession: 009150288

Download citation: RISBibTeXText

PMID: 8625095

DOI: 10.1002/1097-0142(19950715)76:2<223::aid-cncr2820760210>3.0.co;2-4

Related references

Dedifferentiated chondrosarcoma mimicking a giant cell tumor. Is this low grade dedifferentiated chondrosarcoma?. Pathology, Research and Practice 210(3): 194-197, 2014

Different expression of Sox9 and Runx2 between chondrosarcoma and dedifferentiated chondrosarcoma cell line. European Journal of Cancer Prevention 19(6): 466-471, 2011

Chondrosarcoma with additional mesenchymal component (dedifferentiated chondrosarcoma). I. A clinicopathologic study of 26 cases. Cancer 58(2): 278-286, 1986

Chondrosarcoma of the larynx with additional malignant mesenchymal component (dedifferentiated chondrosarcoma). American Journal of Surgical Pathology 12(4): 314-320, 1988

Chondrosarcoma with additional mesenchymal component (dedifferentiated chondrosarcoma). II. An immunohistochemical and electron microscopic study. Cancer 58(2): 287-298, 1986

Three new chondrosarcoma cell lines: one grade III conventional central chondrosarcoma and two dedifferentiated chondrosarcomas of bone. Bmc Cancer 12: 375-375, 2013

Juxtacortical dedifferentiated chondrosarcoma from a primary periosteal chondrosarcoma. Modern Pathology 9(3): 279-283, 1996

Dedifferentiated chondrosarcoma: an aggressive variant of chondrosarcoma. Asian Cardiovascular & Thoracic Annals 23(2): 221-223, 2015

BMPR2-pSMAD1/5 signaling pathway regulates RUNX2 expression and impacts the progression of dedifferentiated chondrosarcoma. American Journal of Cancer Research 6(6): 1302-1316, 2016

Is dedifferentiated chondrosarcoma a 'de-differentiated' chondrosarcoma?. Journal of Pathology 189(4): 445-447, 2000

Case report 347. Dedifferentiated chondrosarcoma: grade 4 fibrosarcoma arising in grade 1 chondrosarcoma (femur). Skeletal Radiology 15(1): 77-81, 1986

Expression of plasminogen activators and plasminogen activator inhibitor 1 in dedifferentiated chondrosarcoma. Cancer. 79(1): 53-58, 1997

Dedifferentiated chondrosarcoma with t(9;22)(q34;q11-12). Genes, Chromosomes & Cancer 9(2): 136-140, 1994

Dedifferentiated chondrosarcoma. Journal of Bone and Joint Surgery. American Volume 70(1): 60-69, 1988

Dedifferentiated chondrosarcoma of the larynx. Pathology Research & Practice 185(1): 144, 1989